The future of facial rejuvenation is evolving beyond simple volume replacement. As aesthetic medicine continues to advance, there is growing interest in approaches that consider how fillers interact with the skin over time, steering the conversation towards hybrid fillers and biostimulation.
At IMCAS 2026, Genefill, powered by BioScience, will lead the discussion on biostimulatory fillers and their growing role in modern aesthetic treatment strategies. The focus? How intelligent product design, like that behind Genefill DX, is changing the clinical conversation from simple correction to long-term skin improvement.
In this blog, we explore key ideas shaping the future of facial aesthetics, what biostimulation truly means, why it matters, and how Genefill DX fits into the evolving clinical landscape.
What Makes Biostimulation the Future?
In aesthetic medicine, biostimulation refers to a filler’s ability to activate the body’s natural regenerative processes by encouraging the production of collagen and elastin. As patient expectations shift toward results that last longer, look more natural, and improve skin quality over time, the demand for biostimulatory solutions has never been higher.1
Unlike traditional HA fillers that focus solely on restoring volume, biostimulatory fillers engage with the skin on a deeper level by supporting skin health and improving its resilience from within. This shift is transforming how practitioners approach non-surgical facial rejuvenation, placing more emphasis on the skin’s biological response than just the aesthetic results.
The Genefill DX Advantage
At the forefront of this innovation is Genefill DX, a next-generation hybrid dermal filler that combines cross-linked hyaluronic acid (HA) with dextranomer (DX) microspheres. This dual formulation is designed to provide immediate hydration and lift through HA, while DX microspheres stimulate collagen production for a long-term rejuvenative effect.
What sets this filler apart is not just its hybrid formulation but its clinically thoughtful design, engineered for tissue integration, durability, and predictable outcomes.
To support this, BioScience recently conducted an in vitro study, evaluating how Genefill DX interacts with key components of the extracellular matrix. The study offers valuable scientific insight into how this HA+DX filler may support collagen production, tissue repair, and hydration when used in practice.2 Our experts will be discussing this study in a bit more detail during IMCAS 2026 to provide a deeper look at how hybrid fillers are advancing scientific understanding in the field.
Smart Aesthetics at IMCAS 2026
We will be taking the stage at IMCAS with a focused symposium, titled: Smart Aesthetics: Hybrid Biostimulatory Excellence for the Face, Targeted Precision for the Body.
Dr. Gabriela Casabona will open the facial aesthetics discussion with The Future of Biostimulation in Facial Aesthetics, setting the stage for a broader conversation on product selection, patient-specific planning, and innovation-driven outcomes.
Dr. Mariam Tsivtsivadze will take the conversation further in her dedicated talk, Genefill DX, the Ultimate HA+DX Hybrid: Clinical Insights Shaping the Biostimulation Era. Her session will offer practical context for how its formulation is uniquely suited to meet the needs of both patients and practitioners seeking more than just surface-level results.
These sessions are part of a broader 90-minute symposium that also explores advanced body contouring with HYAcorp and real-world insights from a panel of international experts.
Join the Conversation
Hybrid fillers represent the next phase in aesthetic medicine, offering benefits that are not only visible but biologically validated. As the field moves toward solutions that deliver visible and biological benefits, Genefill DX, as a filler with HA+DX formulation, stands as a pioneer product of innovation and science.
We invite you to join us at IMCAS World Congress and visit us at the BioScience booth to discover how Smart Aesthetics is changing the way we think about facial rejuvenation, one layer at a time.
Find us in Room 252, Level 2, on January 30th, 2026, at 14:00 CET – at the Palais des Congrès de Paris.
Add the session to your calendar – this is one you don’t want to miss!
References
- Nien HK, Wanitphakdeedecha R, Lee W. Injectable Biostimulators in Regenerative Aesthetics: Mechanisms, Clinical Applications, and Synergistic Approaches. In: Lee W. (eds) Innovative Injectable Techniques in Minimally Invasive Aesthetics. Singapore: Springer; 2025. p. 25-40.
- Ortiz-Flores RM, Escamilla-Sanchez A, Cidoncha-Morcillo B, Mastronardi L, Fontenete S, Garcia-Delgado R. Enhanced Facial Rejuvenation: Biostimulatory Effects of Hylan Gel Dermal Filler DX on Collagen Synthesis and Tissue Regeneration. Aesthetic Plast Surg. 2025 Oct 13.
.webp)
